Major Opioids in Pain Management

SPEC - Essentials of Pain Medicine and Regional Anesthesia (Reprint)

Volumn , Issue , 2005, Pages 94-105

  Mahajan, Gagan ^a   Fishman, Scott M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37349029607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06651-1.50015-0     Document Type: Chapter

References (51)

1. Portenoy RK Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996, 11:203-217.
2. Robinson RC, Gatchel RJ, Polatin P, et al. Screening for problematic prescription opioid use. Clin J Pain 2001, 17:220-228.
3. Pappagallo M, Heinberg LJ Ethical issues in the management of chronic nonmalignant pain. Semin Neurol 1997, 17:203-211.
4. Barkin RL, Barkin D Pharmacologic management of acute and chronic pain: Focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J 2001, 94:756-770.
5. Society AP Principles of analgesic use in the treatment of acute pain and chronic cancer pain. Clini Pharmacy 1990, 9:601-611.
6. Dear Miss Nightingale: A selection of Benjamin Jowett's letters to Florence 1860-1893 1987, Prest VQAJ, Oxford University Press, New York.
7. Bertin P Current use of analgesics for rheumatological pain. Eur J Pain 2000, 4:9-13.
8. Watson CP The treatment of neuropathic pain: Antidepressants and opioids. Clin J Pain 2000, 16:S49-S55.
9. Ossipov MH, Lopez Y, Nichols ML, et al. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 1995, 199:83-86.
10. Mao J, Price DD, Mayer DJ Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995, 61:353-364.
11. McQuay H, Moore R An Evidence-based Resource for Pain Relief 1998, Oxford University Press, Oxford.
12. http://www.ampainsoc.org/advocacy/opioids.htm.
13. Model Guidelines for the Use of Controlled Substances for the Treatment of Pain, 1998. http://www.fsmb.org/.
14. Portenoy RK Current pharmacotherapy of chronic pain. J Pain Symptom Manage 2000, 19:S16-S20.
15. Reder RF Opioid formulations: Tailoring to the needs in chronic pain. Eur J Pain 2001, 5:109-111.
16. Mercadante S, Fulfaro F Alternatives to oral opioids for cancer pain. Oncology (Huntingt) 1999, 13:215-220. 225, discussion 226-229.
17. Dworkin RH, Hetzel RD, Banks SM Toward a model of the pathogenesis of chronic pain. Semin Clin Neuropsychiatry 1999, 4:176-185.
18. Vlaeyen JW, Crombez G Fear of movement/(re)injury, avoidance and pain disability in chronic low back pain patients. Man Ther 1999, 4:187-195.
19. Feldman SI, Downey G, Schaffer-Neitz R Pain, negative mood, and perceived support in chronic pain patients: A daily diary study of people with reflex sympathetic dystrophy syndrome. J Consult Clin Psychol 1999, 67:776-785.
20. Quang-Cantagrel ND, Wallace MS, Magnuson SK Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review. Anesth Analg 2000, 90:933-937.
21. Sarhill N, Walsh D, Nelson KA Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer 2001, 9:84-96.
22. Omoigui S Sota Omoigui's Pain Drugs Handbook 1999, 816. Blackwell Science, Oxford.
23. Janicki PK, Parris WC Clinical pharmacology of opioids. Drugs for Pain 2003, 97-118. Hanley & Belfus, Philadelphia. H.S. Smith (Ed.).
24. Inturrisi CE Clinical pharmacology of opioids for pain. Clin J Pain 2002, 18:S3-S13.
25. Smith MT Neuroexcitatory effects of morphine and hydromor-phone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000, 27:524-528.
26. Osborne R, Joel S, Trew D, Slevin M Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990, 47:12-19.
27. Peterson GM, Randall CT, Paterson J Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: Relationship to renal function and route of administration. Eur J Pharmacol 1990, 38:121-124.
28. Anderson R, Saiers JH, Abram S, Schlicht C Accuracy in equianalgesic dosing. Conversion dilemmas. J Pain Symptom Manage 2001, 21:397-406.
29. Kaplan R, Parris WC, Citron ML, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998, 16:3230-3237.
30. Levy MH Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 2001, 5:113-116.
31. Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996, 59:52-61.
32. Coda B, Tanaka A, Jacobson RC, et al. Hydromorphone analgesia after intravenous bolus administration. Pain 1997, 71:41-48.
33. The American Heritage Stedman's Medical Dictionary, vol xxxiii. Houghton Mifflin, Boston, 2002, p 923.
34. Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective phar-macokinetics of methadone in chronic pain patients. Ther Drug Monit 1996, 18:221-227.
35. Rostami-Hodjegan A, Wolff K, Hay AW, et al. Population phar-macokinetics of methadone in opiate users: Characterization of time-dependent changes. Br J Clin Pharmacol 1999, 48:43-52.
36. Fishman SM, Wilsey B, Mahajan G, Molina P Methadone reincarnated: Novel clinical applications with related concerns. Pain Medicine 2002, 3:339-348.
37. Davis MP, Walsh D Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions, and protocols of administration. Support Care Cancer 2001, 9:73-83.
38. Liu JG, Liao XP, Gong ZH, Qin BY The difference between methadone and morphine in regulation of delta-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions. Eur J Pharmacol 1999, 373:233-239.
39. Gagnon B, Bruera E Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999, 18:120-125.
40. Sang CN NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials. J Pain Symptom Manage 2000, 19:S21-S25.
41. Price DD, Mayer DJ, Mao J, Caruso FS NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage 2000, 19:S7-S11.
42. Parsons CG NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001, 429:71-78.
43. Wolff K, Hay AW, Raistrick D, Calvert R Steady-state pharma-cokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993, 44:189-194.
44. Inturrisi CE, Colburn WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987, 41:392-401.
45. Garrido MJ, Troconiz IF Methadone: A review of its pharmaco-kinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods 1999, 42:61-66.
46. Fainsinger R, Schoeller T, Bruera E Methadone in the management of cancer pain: A review. Pain 1993, 52:137-147.
47. Sandler A Transdermal fentanyl: Acute analgesic clinical studies. J Pain Symptom Manage 1992, 7:S27-S35.
48. Gourlay GK Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2001, 2:165-172.
49. Gourlay GK, Kowalski SR, Plummer JL, et al. The transdermal administration of fentanyl in the treatment of postoperative pain: Pharmacokinetics and pharmacodynamic effects. Pain 1989, 37:193-202.
50. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001, 91:123-130.
51. Lichtor JL, Sevarino FB, Joshi GP, et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 1999, 89:732-738.